Pacira BioSciences, Inc. (PCRX) stock
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)
Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –
Pacira BioSciences gross margin
Gross margin is gross profit as a percentage of revenue.
Pacira BioSciences's gross margin for the twelve months ending Jun 30, 2026 was 79.2%. For fiscal 2025 it was 79.4%, against 75.7% the year before. The highest annual figure on record is 79.4% in fiscal 2025.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 79.4% | +3.7 |
| FY2024 | Dec 31, 2024 | 75.7% | +3.0 |
| FY2023 | Dec 31, 2023 | 72.6% | +2.5 |
| FY2022 | Dec 31, 2022 | 70.1% | −4.0 |
| FY2021 | Dec 31, 2021 | 74.1% | +1.4 |
| FY2020 | Dec 31, 2020 | 72.7% | −2.0 |
| FY2019 | Dec 31, 2019 | 74.7% | +0.4 |
| FY2018 | Dec 31, 2018 | 74.3% | +4.9 |
| FY2017 | Dec 31, 2017 | 69.3% | +9.2 |
| FY2016 | Dec 31, 2016 | 60.2% | −11.0 |
| FY2015 | Dec 31, 2015 | 71.1% | +10.3 |
| FY2014 | Dec 31, 2014 | 60.8% | +24.8 |
| FY2013 | Dec 31, 2013 | 36.0% | +18.2 |
| FY2012 | Dec 31, 2012 | 17.8% | +24.5 |
| FY2011 | Dec 31, 2011 | -6.7% | −22.4 |
| FY2010 | Dec 31, 2010 | 15.7% | −2.3 |
| FY2009 | Dec 31, 2009 | 18.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 77.0% | −0.4 |
| Q1 FY2026 | Mar 31, 2026 | 79.5% | −0.2 |
| Q4 FY2025 | Dec 31, 2025 | 79.5% | +0.8 |
| Q3 FY2025 | Sep 30, 2025 | 80.9% | +4.0 |
| Q2 FY2025 | Jun 30, 2025 | 77.4% | +2.3 |
| Q1 FY2025 | Mar 31, 2025 | 79.7% | +8.1 |
| Q4 FY2024 | Dec 31, 2024 | 78.7% | +5.0 |
| Q3 FY2024 | Sep 30, 2024 | 76.9% | +1.2 |
| Q2 FY2024 | Jun 30, 2024 | 75.1% | +3.6 |
| Q1 FY2024 | Mar 31, 2024 | 71.6% | +2.2 |
| Q4 FY2023 | Dec 31, 2023 | 73.7% | +9.7 |
| Q3 FY2023 | Sep 30, 2023 | 75.8% | +6.0 |
| Q2 FY2023 | Jun 30, 2023 | 71.6% | +1.4 |
| Q1 FY2023 | Mar 31, 2023 | 69.4% | −7.7 |
| Q4 FY2022 | Dec 31, 2022 | 64.0% | −11.5 |
| Q3 FY2022 | Sep 30, 2022 | 69.7% | −3.1 |
| Q2 FY2022 | Jun 30, 2022 | 70.1% | −3.9 |
| Q1 FY2022 | Mar 31, 2022 | 77.2% | +3.5 |
| Q4 FY2021 | Dec 31, 2021 | 75.5% | +2.4 |
| Q3 FY2021 | Sep 30, 2021 | 72.9% | −1.6 |
| Q2 FY2021 | Jun 30, 2021 | 74.0% | +3.5 |
| Q1 FY2021 | Mar 31, 2021 | 73.7% | +1.8 |
| Q4 FY2020 | Dec 31, 2020 | 73.0% | −0.9 |
| Q3 FY2020 | Sep 30, 2020 | 74.5% | −4.2 |
| Q2 FY2020 | Jun 30, 2020 | 70.5% | −5.0 |
| Q1 FY2020 | Mar 31, 2020 | 71.9% | +1.8 |
| Q4 FY2019 | Dec 31, 2019 | 73.9% | −0.8 |
| Q3 FY2019 | Sep 30, 2019 | 78.7% | +1.5 |
| Q2 FY2019 | Jun 30, 2019 | 75.4% | +0.3 |
| Q1 FY2019 | Mar 31, 2019 | 70.1% | +0.8 |
| Q4 FY2018 | Dec 31, 2018 | 74.8% | +1.7 |
| Q3 FY2018 | Sep 30, 2018 | 77.2% | +4.2 |
| Q2 FY2018 | Jun 30, 2018 | 75.1% | +8.7 |
| Q1 FY2018 | Mar 31, 2018 | 69.3% | +4.8 |
| Q4 FY2017 | Dec 31, 2017 | 73.1% | +5.5 |
| Q3 FY2017 | Sep 30, 2017 | 72.9% | +36.1 |
| Q2 FY2017 | Jun 30, 2017 | 66.4% | – |
| Q1 FY2017 | Mar 31, 2017 | 64.5% | – |
| Q4 FY2016 | Dec 31, 2016 | 67.6% | – |
| Q3 FY2016 | Sep 30, 2016 | 36.9% | – |
See a number that looks wrong?